Metraipolis › archive › dc_277dc173e515
Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy — Europe PMC PMID:42195328
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42195328
- DOI
- 10.3390/life16050772
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T19:01:15.376Z
- SHA-256 of the archived text
6453cd888d38f32b8762dec2bfc98dc6b34096c1292580f8856cbb5167467fe6- Stable URL of this page
https://metraipolis.com/documento/dc_277dc173e515
How to cite
Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy — Europe PMC PMID:42195328 — Europe PMC (en), https://europepmc.org/article/MED/42195328 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_277dc173e515 (Metraipolis archive dc_277dc173e515, sha256 6453cd888d38f32b8762dec2bfc98dc6b34096c1292580f8856cbb5167467fe6)
BibTeX
@misc{dc277dc173e515,
title = {Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy — Europe PMC PMID:42195328},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42195328},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_277dc173e515; sha256 6453cd888d38f32b8762dec2bfc98dc6b34096c1292580f8856cbb5167467fe6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195328. Agents can read the archived copy with the MCP tool read_document.